The Impact of US Patent Linkage on Marketing of Generic Drugs.
碩士 === 國立雲林科技大學 === 科技法律研究所 === 103 === Patent linkage system involves linking generic drug marketing approval with the originator drug’s patent status and refusing marketing approval until the relevant patent expires. However, generic pharmaceutical marketing as main market in Taiwan, and there is...
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Others |
Language: | zh-TW |
Published: |
2015
|
Online Access: | http://ndltd.ncl.edu.tw/handle/10912532232187830025 |
id |
ndltd-TW-103YUNT0705011 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-TW-103YUNT07050112016-07-02T04:21:22Z http://ndltd.ncl.edu.tw/handle/10912532232187830025 The Impact of US Patent Linkage on Marketing of Generic Drugs. 美國專利連結制度對學名藥廠影響之研究 Yang Jhen-Hong 楊鎮鴻 碩士 國立雲林科技大學 科技法律研究所 103 Patent linkage system involves linking generic drug marketing approval with the originator drug’s patent status and refusing marketing approval until the relevant patent expires. However, generic pharmaceutical marketing as main market in Taiwan, and there is no patent linkage system in Taiwan, so there are still doubts about bringing in patent linkage system. For solve these question, first we discuss the legislative history and Current status of patent linkage system in US and the regulation of Biomedical and pharmaceutical in Taiwan. And then we discuss the impact of patent linkage on marketing of Generic drugs through the case “Novo Nordisk A/S v. Caraco Pharm. Labs, Ltd.”. In the end, we analysis the impact of patent linkage on Taiwan’s marketing of Generic drugs and discuss our government whether can introduce patent linkage system into Taiwan or not. Tsai Yueh-Hsun 蔡岳勳 2015 學位論文 ; thesis 95 zh-TW |
collection |
NDLTD |
language |
zh-TW |
format |
Others
|
sources |
NDLTD |
description |
碩士 === 國立雲林科技大學 === 科技法律研究所 === 103 === Patent linkage system involves linking generic drug marketing approval with the originator drug’s patent status and refusing marketing approval until the relevant patent expires. However, generic pharmaceutical marketing as main market in Taiwan, and there is no patent linkage system in Taiwan, so there are still doubts about bringing in patent linkage system. For solve these question, first we discuss the legislative history and Current status of patent linkage system in US and the regulation of Biomedical and pharmaceutical in Taiwan. And then we discuss the impact of patent linkage on marketing of Generic drugs through the case “Novo Nordisk A/S v. Caraco Pharm. Labs, Ltd.”. In the end, we analysis the impact of patent linkage on Taiwan’s marketing of Generic drugs and discuss our government whether can introduce patent linkage system into Taiwan or not.
|
author2 |
Tsai Yueh-Hsun |
author_facet |
Tsai Yueh-Hsun Yang Jhen-Hong 楊鎮鴻 |
author |
Yang Jhen-Hong 楊鎮鴻 |
spellingShingle |
Yang Jhen-Hong 楊鎮鴻 The Impact of US Patent Linkage on Marketing of Generic Drugs. |
author_sort |
Yang Jhen-Hong |
title |
The Impact of US Patent Linkage on Marketing of Generic Drugs. |
title_short |
The Impact of US Patent Linkage on Marketing of Generic Drugs. |
title_full |
The Impact of US Patent Linkage on Marketing of Generic Drugs. |
title_fullStr |
The Impact of US Patent Linkage on Marketing of Generic Drugs. |
title_full_unstemmed |
The Impact of US Patent Linkage on Marketing of Generic Drugs. |
title_sort |
impact of us patent linkage on marketing of generic drugs. |
publishDate |
2015 |
url |
http://ndltd.ncl.edu.tw/handle/10912532232187830025 |
work_keys_str_mv |
AT yangjhenhong theimpactofuspatentlinkageonmarketingofgenericdrugs AT yángzhènhóng theimpactofuspatentlinkageonmarketingofgenericdrugs AT yangjhenhong měiguózhuānlìliánjiézhìdùduìxuémíngyàochǎngyǐngxiǎngzhīyánjiū AT yángzhènhóng měiguózhuānlìliánjiézhìdùduìxuémíngyàochǎngyǐngxiǎngzhīyánjiū AT yangjhenhong impactofuspatentlinkageonmarketingofgenericdrugs AT yángzhènhóng impactofuspatentlinkageonmarketingofgenericdrugs |
_version_ |
1718333610691395584 |